UPMC Hillman Cancer Center
Pittsburgh's NCI comprehensive centre: Bernard Fisher's NSABP home, discoverer of two cancer viruses, and a leader in melanoma and LAG-3 immunotherapy.
NCI comprehensive since 1990, UPMC Hillman spans western Pennsylvania through UPMC's network. Bernard Fisher led the NSABP from Pittsburgh, proving with B-06 that lumpectomy plus radiation equals mastectomy and with P-1 that tamoxifen prevents breast cancer; NSABP lives on within NRG Oncology. Yuan Chang and Patrick Moore discovered Kaposi sarcoma herpesvirus in 1994 and Merkel cell polyomavirus in 2008. Dario Vignali's LAG-3 biology underpins relatlimab, Hassane Zarour and Diwakar Davar showed faecal microbiota transplant can overcome anti-PD-1 resistance in melanoma, and Greg Delgoffe studies T-cell metabolism in tumours. The centre also has a large head and neck cancer immunotherapy programme.
- Breast cancer trials (NSABP heritage)
- Tumour virology
- Melanoma immunotherapy and microbiome
- LAG-3 biology
Pages like this
not linked directly; found by shared links- TrialRELATIVITY-098
Shares Relatlimab + nivolumab, LAG-3, Melanoma.
- PairingCaution: LAG-3 blockade outside active disease
Shares Relatlimab + nivolumab, LAG-3, Melanoma.
- TrialRELATIVITY-047
Shares Relatlimab + nivolumab, LAG-3, Melanoma.
- PersonBernard Fisher
Shares Tamoxifen, NRG Oncology, HR-positive / HER2-negative breast cancer.
- Key paperRELATIVITY-047: relatlimab plus nivolumab, the first LAG-3 checkpoint combination, in untreated advanced melanoma
Shares Relatlimab + nivolumab, LAG-3, Melanoma.
- InstitutionIstituto Nazionale Tumori IRCCS Fondazione G. Pascale
Shares Relatlimab + nivolumab, LAG-3, Melanoma.
- TechnologyElectrochemotherapy
Shares Kaposi sarcoma, Head and neck squamous cell carcinoma, Melanoma.
- ProductTechnetium-99m tilmanocept
Shares Head and neck squamous cell carcinoma, Melanoma, HR-positive / HER2-negative breast cancer.